ABSTRACT
Introduction
Cancer is a major public health and economical concern. Multidisciplinary approach with surgery, radiotherapy and chemotherapy has resulted in significant reduction in the mortality [1] . Treatment for cancer has improved significantly over the years and has proved to reduce recurrences as well as increase the rate of cure. Chemotherapy is one of the principle areas of development in the history of cancer treatment. However, the applicability of these drugs has been limited by their effect of cardiotoxicity [2] .
A variety of chemotherapeutic agents have been in use. Current cancer treatments incorporate multiple agents whose deleterious effects may be additive or synergetic. Cytostatic antibiotics of anthracycline class are the most recognized ones for their cadiotoxicity, but other chemotherapeutic agents such as alkylating agents can also cause serious cardiotoxicity. Anthracycline chemotherapy regimens play a major role in many cancer treatments like breast carcinoma, sarcoma, lymphoma, gynecological cancers and childhood cancers [3, 4] . Thus, with long term cancer survivorship there will be a substantial group of cancer patients who will remain at risk of early cardiovascular morbidity and mortality due to their anthracycline chemotherapy [5, 6] .
Cardiotoxicity can appear either early (within days) or late (within months or years later) in the course of the disease and may vary from subclinical myocardial dysfunction to irreversible heart failure or even death. Limited data is available on mechanism of developing cardiac dysfunction and susceptibility of patients for the same [7] . Recent consensus statements define chemotherapy induced cardio toxicity as a decrease in the Left Ventricular Ejection Fraction (LVEF) of more than 10% to a value less than 55%, confirmed by repeated cardiac imaging [8] . Echocardiography is the technique of choice in the cardiac imaging of patients before, during and after cancer chemotherapy because of its wide availability, easy repeatability, versatility, lack of radiation exposure, and safety in this group of patients. Speckle-tracking echocardiography is a new noninvasive imaging technique of echocardiography that allows an objective and quantitative evaluation of global and regional myocardial function [9] . By tracking the displacement of speckles during the cardiac cycle, speckle-tracking echocardiography allows semi-automated elaboration of myocardial deformation in 3 spatial directions: longitudinal, radial and Circumferential. In addition, speckle-tracking echocardiography offers an evaluation of the occurrence, direction and velocity of left ventricle (LV) rotation [10] . 
Methods
The present study was conducted between November 2015 and October 2017. 54 consecutive patients above 18 years of age who were diagnosed to have breast cancer prior to consultation and had been advised anthracyline group of chemotherapy agents were included. Ethical clearance was obtained from ethical committee of J. N. Medical College. Patients who had a previous history of myocardial injury, received radiotherapy and those with LV dysfunction at baseline were excluded. Anthropometric data in regards to height, weight, BMI and baseline characteristics such as cancer variant, chemotherapy regimens were entered in a pre-structured proforma. All subjects underwent a baseline echocardiographic examination which was ECG gated and 2D speckle tracking transthoracic analysis was done offline. Images acquired included all the below mentioned but not limited to a parasternal short axis view at apical, mid and basal levels and an apical 4, 3 and 2 chamber view by real time acquisition. Echocardiographic examination was repeated after each scheduled cycle of anthracyline chemotherapy. In patients who had symptoms or signs of heart failure and/or in those who developed echocardiographically definable LV dysfunction, the chemotherapy was stopped and the patient was followed up. In all the other patients, they underwent an echocardiographic examination at 3, 6 and 12 months intervals.
After offline analysis with automated software installed in EPIQ 7C echo machine on each view of long and short axis views, the left ventricular endocardial borders were manually traced. Longitudinal strain was derived by using apical 2-chamber, 3-chamber, 4-chamber views whereas circumferential by parasternal Short Axis at basal, mid and apical level and finally global strain of longitudinal and circumferential (Bull's eye) were obtained in every patient during each assessment.
Results
54 patients were included in the study. The mean age was 58 ± 15 years. The baseline characteristics of the study population are depicted in Table 1 . 14.8% (n=8) developed LV dysfunction (Figure 1 ). 
Echocardiographic findings
Baseline and post completion of chemotherapy parameters in both the groups is depicted in Table 2 . 
Strain Imaging
Global longitudinal strain and circumferential strain were done during each visit. In 2 patients who had 6% and 8% drop in LV EF post chemotherapy, the Global Longitudinal Strain was reduced by 16% and 18% respectively, which is a significant drop. Moreover the same 2 patients went on to develop definable LV Dysfunction at the end of 3 months post chemotherapy. This shows that strain parameters can detect early onset LV Dysfunction while being easily reproducible.
Follow up
On follow up, at 3 months out of the 8 patients who had developed LV Dysfucntion, 6 patients continued to have persistent LV dysfunction whereas 2 patients recovered. At long term follow up of 12 months; it was found that all the 6 patients who had LV dysfunction at the end of 3 months continued to have LV dysfunction (Figure 2 ).
Chemotherapeutic agent
The mean cumulative dosage of doxorubicin in the LV Dysfunction group was 350 ± 46.2 mg/m 2 , where as in the non LV Dysfunction group it was 340 ± 42.2mg/m 2 . With respect to epirubicin, the mean cumulative dose was 132 ± 154mg/m 2 in the LV Dysfunction group and 144 ± 128mg/m 2 in the non LV Dysfunction group. Both were not found to be statistically significant.
Discussion
In the present, we evaluated chemotherapy induced LV dysfunction in patients undergoing chemotherapy with anthracyclines. Advanced age, low BMI, Diabetes, advanced cancer stage, number of chemotherapy cycles were all found to be associated with increased risk of developing chemotherapy induced LV dysfunction. Chemotherapeutic agent and their cumulative dosage when measured per m2 of the body surface area did not correlate with the risk of developing LV dysfunction. Among the patients who developed LV dysfunction post chemotherapy, majority (75%) of them had persistent LV dysfunction after 3 months of the onset of LV dysfunction. In those who had LV dysfunction at the end of 3 months, it was found that all of them remained in LV dysfunction even on long-term follow-up. Cancer survival, especially in the initial stages has shown increased survival rates owing to earlier diagnosis. The adverse effects of chemotherapy, such as cardiotoxicity have been on the rise and have become a paramount issue for cancer patient survival and morbidity. Chemotherapy induced cardiomyopathy secondary to Anthracyclines has been known [11] . In our study Anthracycline induced LV dysfunction developed in 14.8% of the study population. Although the study included only 54 patients who are undergoing chemotherapy, similar studies in the Indian subcontinent have not been done and further prospective studies are necessary to evaluate the same.
The present study showed that LVEF and Global strain parameters were reduced not only in the LV Dysfunction group, but also in the Non LV Dysfunction group suggesting subclinical LV Dysfunction even in the Non LV Dysfunction group. This further signifies the importance of early and correct recognition of chemotherapy induced LV Dysfunction in such patients.
The present study had several limitations. The study population was only 54 patients in whom both baseline and follow-up echocardiographic examinations were done, so it cannot be generalized for the whole patient population who receive Anthracyclines. The medication details regarding treatment for chemotherapy induced LV dysfunction were not analysed in the present study which could throw light on why majority of the LV Dysfucntion patients failed to recover during follow-up. A routine Coronary angiography was not performed in all patients and hence it was not included in the analysis, however those patients who were found to have coronary artery disease were excluded from the study.
Conclusion
The study demonstrated the presence of Chemotherapy induced LV Dysfucntion in patients receiving Anthracylines group of chemotherapy. Age, low BMI, diabetes, advanced cancer stage are all associated with higher risk of developing LV Dysfunction post chemotherapy. Careful monitoring with non-invasive modalities such as strain imaging are ideal for early detection of LV dysfunction.
